t-16

Antiproliferative agent-16 (Antiproliferative agent-16) is an indolyl hydrazide-hydrazone compound with anticancer activity. Antiproliferative agent-16 exhibits specificity toward breast cancer cells (IC50 of 6.94 μM for MCF-7 cells).

Antitumor agent-160 (compound Ia) is a derivative of the antifungal agent PHENALENONE and exhibits antitumor activity.

Antibiofilm agent-15 (Compound 17) is an antimicrobial agent that inhibits biofilm formation of both Gram-positive and Gram-negative bacteria.

PET-16 is a HSP70 inhibitor.

ST-168 is a potent inhibitor of PI3K and MEK. ST-168 displays improved PI3K and MEK1 isoform inhibition. ST-168 demonstrated a 2.8-, 2.7-, 23-, and 2.5-fold improved inhibition toward the PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ isoforms and a 2.2-fold improvement

5α-Androst-16-en-3α-ol is a steroid pheromone that has been found in boar testes and human male axillary sweat and has diverse biological activities.1,2It enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50= 0.4 μM).25α-Androst-16-en-3α-ol (0.1-1 μM) increases the amplitude of GABA-activated currents in HEK293 cells expressing human α1β2γ2and α2β2γ2subunit-containing GABAAreceptors.In vivo, 5α-androst-16-en-3α-ol (5-10 mg kg) decreases immobility time in the forced swim test in mice. It increases time spent in the open arms of the elevated plus maze in mice, indicating anxiolytic-like activity, when administered at doses ranging from 30 to 50 mg kg. 5α-Androst-16-en-3α-ol protects against seizures induced by pentylenetetrazole or electroshock in mice (ED50s = 48.9 and 21.9 mg kg, respectively). 1.Brooksbank, B.W., Brown, R., and Gustafsson, J.A.The detection of 5α-androst-16-en-3α-ol in human male axillary sweatExperientia30(8)864-865(1974) 2.Kaminski, R.M., Marini, H., Ortinski, P.I., et al.The pheromone androstenol (5α-androst-16-en-3α-ol) is a neurosteroid positive modulator of GABAA receptorsJ. Pharmacol. Exp. Ther.317(2)694-703(2006)

Antitubercular agent-16 (Compound 5q) is a potent antitubercular agent exhibiting high efficacy against various strains of M. tuberculosis, including H37Rv, CF16, CF61, CF76, CF152, and CF161, with MIC 90 values ranging from 0.40 to 23.51 μg mL. Notably, Antitubercular agent-16 demonstrates minimal cytotoxicity towards macrophages and pulmonary fibroblasts, further highlighting its potential as a therapeutic agent [1].

WT161 is a potent and selective inhibitor of HDAC6 (IC50:0.40 nM).

Antileishmanial agent-16 (compound 14c), an anti-Leishmania agent, exhibits potent activity against Leishmania major promastigotes (IC50 = 0.59 µM) and amastigotes (IC50 = 0.81 µM), while maintaining a favorable safety profile in mammalian cells (VERO cells) [1].

Antioxidant Agent-16 (Product 2) exhibits potent antioxidant activity, as demonstrated by its IC50 value of 6.93 ppm [1].

5α-Androst-16-en-3-one, a mammalian pheromone present in boar saliva, plays a crucial role in facilitating social and sexual interactions by acting as a volatile chemical cue. It is utilized to prime sows in estrus for mating or artificial insemination, underscoring its significance in reproductive behavior. Additionally, this compound is detected in human sweat and urine, where it is involved in studies concerning receptor-mediated odorant detection and the genetic foundations of anosmias, thereby broadening its scope of relevance beyond the animal kingdom.

Antitumor agent-164 (compound 60c), a next-generation derivative of VERU-111, serves as a colchicine binding site inhibitor (CBSI). It is effective against taxane-sensitive triple-negative breast cancer (TNBC).

Antitumor agent-168 (compound 21b) disrupts the microtubule networks within tumor cells, leading to G2 M cell cycle arrest and induction of apoptosis. It inhibits the growth of MCF-7 cells with an IC50 value of 1.4 nM.

ent-16-Kaurene-3beta,15beta,18-triol, ent-16-kaurene-3beta,15beta-diol,abbeokutone,and helioscopinolide A possess appreciable anti-allergic activities in RBL-2H3 cells model with IC50 values ranging from 22.5 to 42.2 microM.

ent-16alpha,17-Dihydroxyatisan-3-one and ent-16alpha,17-dihydroxykauran-3-one have apoptosis induction activities on L5178 human MDR1 gene-transfected mouse lymphoma cells.

ent-16beta,17-Dihydroxy-19-kauranoic acid is a natural product for research related to life sciences. The catalog number is TN3938 and the CAS number is 3301-61-9.

ent-16beta,17-dihydroxy-9(11)-kauren-19-oic acid is a natural product of Xanthium, Asteraceae. The catalog number is TN3939 and the CAS number is 55483-24-4. ent-16beta,17-dihydroxy-9(11)-kauren-19-oic acid can be used as a reference standard.

ent-16beta,17-Isopropylidenedioxykaurane is a natural product for research related to life sciences. The catalog number is TN3940 and the CAS number is 58493-71-3.

GNF4877 is a potent inhibitor of DYRK1A and GSK3β (IC50s: 6 nM and 16 nM, respectively), resulting in the blockade of nuclear export of nuclear factor of activated T-cells (NFATc) and increased β-cell proliferation.

TP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.

DSPE-PEG(2000)-mannose, a pegylated and mannosylated derivative of 1,2-DSPE, has been employed in both in vitro and in vivo studies for delivering peptides, oligodeoxynucleotides, and siRNA via liposomes and lipid nanoparticles (LNPs). Fluorescently labeled LNPs containing DSPE-PEG(2000)-mannose predominantly accumulate in the liver and spleen of mice, significantly more so than in the brain, lungs, heart, kidneys, and pancreas. In immunization studies, liposomes encapsulating Human Papillomavirus type 16 (HPV16) E7 peptides with CpG oligodeoxynucleotides as an adjuvant led to reduced tumor volume and decreased numbers of CD4+ or CD8+ T cells and angiogenesis within tumors in a mouse lung cancer model using TC-1 cells.

HPK1-IN-54 (Compound 16) is a potent inhibitor of HPK1 (hematopoietic progenitor kinase 1), enhancing T cell activation and proliferation by blocking HPK1 activity to exert antitumor effects. It has an IC50 of 2.67 nM for HPK1, showing excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 exhibits moderate in vivo clearance and reasonable oral exposure in both mice and rats. Additionally, in the CT26 mouse colon cancer model, HPK1-IN-54 demonstrates significant antitumor activity and shows a synergistic effect when combined with anti-PD-1 therapy. HPK1-IN-54 holds promise for research in the field of immunology.

PKN3-IN-1 (compound 16) inhibits PKN3 (serine threonine-protein kinase N3) and GAK (cyclin G-associated kinase) with an IC50 of 0.014 μM and a Ki of 0.0044 μM. PKN3-IN-1 is a potential tool compound for investigating the cell biology of PKN3 and its role in pancreatic and prostate cancers, as well as T-cell acute lymphoblastic leukemia.

Palmitic acid-13C is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid is a 16-carbon saturated fatty acid. It comprises approximately 25% of human total plasma lipids.1 It increases protein levels of COX-2 in RAW 264.7 cells when used at a concentration of 75 μM.2 Palmitic acid is involved in the acylation of proteins to anchor membrane-bound proteins to the lipid bilayer.2,3,4,5,6 |1. Santos, M.J., López-Jurado, M., Llopis, J., et al. Influence of dietary supplementation with fish oil on plasma fatty acid composition in coronary heart disease patients. Ann. Nutr. Metab. 39(1), 52-62 (1995).|2. Lee, J.Y., Sohn, K.H., Rhee, S.H., et al. Saturated fatty acids, but not unsaturated fatty acids, induced the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J. Biol. Chem. 276(20), 16683-16689 (2001).|3. Dietzen, D.J., Hastings, W.R., and Lublin, D.M. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. J. Biol. Chem. 270(12), 6838-6842 (1995).|4. Robinson, L.J., and Michel, T. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc. Nat. Acad. Sci. USA 92(25), 11776-11780 (1995).|5. Topinka, J.R., and Bredt, D.S. N-terminal palmitoylation of PSD-95 regulates association with cell membranes and interaction with K+ channel Kv1.4. Neuron 20(1), 125-134 (1998).|6. Miggin, S.M., Lawler, O.A., and Kinsella, B.T. Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J. Biol. Chem. 278(9), 6947-6958 (2003).